IP Library › Granted Patent US 10,023,573
Granted Patent B2
US 10,023,573 · App. 15/583,238 · Granted Jul 17, 2018

Beta-lactamase inhibitor and process for preparing the same

Inventors: Takao Abe (Kanagawa, JP); Takeshi Furuuchi (Kanagawa, JP); Yoshiaki Sakamaki (Kanagawa, JP); Seiichi Inamura (Kanagawa, JP); Akihiro Morinaka (Kanagawa, JP)
Assignee: MEIJI SEIKA PHARMA CO., LTD.
C07D471/08A61K31/407A61K31/4162A61K31/427A61K31/43A61K31/437A61K31/439A61K31/444A61K31/4545A61K31/5377A61K31/545A61K31/546A61K45/06C07D211/60C07F7/0812Y02P20/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,023,573
App. No.
15/583,238
Granted
Jul 17, 2018
Kind
B2
Abstract

A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC 1-6 alkyl; C represents a benzyl group; Rc represents a C 1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

Claims (22)

1. A process for preparing a diazabicyclooctane compound represented by the following formula (I):

wherein A represents RcO—; B represents NH or NC 1-6 alkyl; C represents SO 3 M, wherein M represents H, an inorganic cation or an organic cation; Rc represents a C 1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process comprises:

(a) subjecting to coupling a compound represented by the following formula (IV-a):

wherein in the formula (IV-a), P 1 represents a protective group which can be removed by an acid, a base or a nucleophilic agent; and OBn represents benzyloxy, with a compound having the formula RcOBH in the presence of an active ester, an active amide or a dehydration condensing agent to prepare a compound represented by the following formula (IV-b):

wherein in the formula (IV-b), P 1 represents a protective group which can be removed by an acid, a base or a nucleophilic agent; and OBn represents benzyloxy,

(b) deprotecting P 1 to prepare a compound represented by the following formula (IV-c):

wherein in the formula (IV-c), OBn represents benzyloxy,

(c) silylating the compound of the formula (IV-c),

(d) carrying out an intramolecular urea formation reaction to prepare a compound represented by the following formula (IIa):

wherein in the formula (IIa), OBn represents benzyloxy,

(e) removing the benzyl group of the benzyloxy at the 6-position of the formula (IIa) in the presence of a hydrogenolysis catalyst under a hydrogen atmosphere to prepare a compound represented by the following formula (IIb):

and (f) sulfating the hydroxyl group at the 6-position of the formula (IIb) in the presence of a base, and optionally, deprotecting the protective group in the side chain RcOB—.

2. A process for preparing a diazabicyclooctane compound represented by the following formula (I):

wherein A represents RcO—; B represents NH or NC 1-6 alkyl; C represents a benzyl group; Rc represents a C 1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process comprises:

(a) subjecting to coupling a compound represented by the following formula (IV-a):

wherein in the formula (IV-a), P 1 represents a protective group which can be removed by an acid, a base or a nucleophilic agent; and OBn represents benzyloxy,

with a compound RcOBH in the presence of an active ester, an active amide or a dehydration condensing agent to prepare a compound represented by the following formula (IV-b):

wherein in the formula (IV-b), P 1 represents a protective group which can be removed by an acid, a base or a nucleophilic agent; OBn represents benzyloxy,

(b) deprotecting P 1 to prepare a compound represented by the following formula (IV-c):

wherein in the formula (IV-c), OBn represents benzyloxy,

(c) silylating the compound of formula (IV-c), and

(d) carrying out an intramolecular urea formation reaction.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2017
From: ABE, TAKAO; FURUUCHI, TAKESHI; SAKAMAKI, YOSHIAKI; INAMURA, SEIICHI; MORINAKA, AKIHIRO
To: MEIJI SEIKA PHARMA CO., LTD.
Reel/Frame 042194/0898 →
Priority Claims (1)
JP 2012-122603 · May 30, 2012 · national
Continuity (3)
Division 14872988 · Oct 1, 2015
Division 14404288
Related Publication 20170233393A1 · Aug 17, 2017
Cited By (1)
US 12,221,443